# reload+after+2024-01-22 17:46:14.472550
address1§6000 Shoreline Court
address2§Suite 102
city§South San Francisco
state§CA
zip§94080
country§United States
phone§925 407 1049
website§https://www.nkartatx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
fullTimeEmployees§167
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Paul J. Hastings', 'age': 63, 'title': 'CEO, President & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 938414, 'exercisedValue': 0, 'unexercisedValue': 1016711}, {'maxAge': 1, 'name': 'Dr. Alicia J. Hager', 'age': 53, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 590941, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alyssa  Levin C.A., CPA', 'age': 38, 'title': 'Chief Financial & Business Officer and Principal Accounting Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ralph  Brandenberger Ph.D.', 'age': 54, 'title': 'Chief Technical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James  Trager Ph.D.', 'age': 60, 'title': 'Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Greg  Mann', 'title': 'Vice President of Public Affairs and Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David R. Shook M.D.', 'age': 45, 'title': 'Chief Medical Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§5
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.619
currency§USD
dateShortInterest§1702598400
forwardEps§-2.37
exchange§NMS
quoteType§EQUITY
shortName§Nkarta, Inc.
longName§Nkarta, Inc.
firstTradeDateEpochUtc§1594387800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f8b318d7-cd1e-386d-9dfd-185f3cf0df4b
gmtOffSetMilliseconds§-18000000
targetHighPrice§25.0
targetLowPrice§9.0
targetMeanPrice§14.63
targetMedianPrice§15.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§10.749
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
